516
IRUS TotalDownloads
Altmetric
Clinical Safety and Feasibility of the Advanced Bolus Calculator for Type 1 Diabetes Based on Case-Based Reasoning: A 6-Week Nonrandomized Single-Arm Pilot Study
File | Description | Size | Format | |
---|---|---|---|---|
ReddyManuscript_revised_30.04.16.pdf | Accepted version | 183.53 kB | Adobe PDF | View/Open |
Title: | Clinical Safety and Feasibility of the Advanced Bolus Calculator for Type 1 Diabetes Based on Case-Based Reasoning: A 6-Week Nonrandomized Single-Arm Pilot Study |
Authors: | Reddy, M Pesl, P Xenou, M Toumazou, C Johnston, D Georgiou, P Herrero, P Oliver, N |
Item Type: | Journal Article |
Abstract: | Background: The Advanced Bolus Calculator for Diabetes (ABC4D) is an insulin bolus dose decision support system based on case-based reasoning (CBR). The system is implemented in a smartphone application to provide personalized and adaptive insulin bolus advice for people with type 1 diabetes. We aimed to assess proof of concept, safety, and feasibility of ABC4D in a free-living environment over 6 weeks. Methods: Prospective nonrandomized single-arm pilot study. Participants used the ABC4D smartphone application for 6 weeks in their home environment, attending the clinical research facility weekly for data upload, revision, and adaptation of the CBR case base. The primary outcome was postprandial hypoglycemia. Results: Ten adults with type 1 diabetes, on multiple daily injections of insulin, mean (standard deviation) age 47 (17), diabetes duration 25 (16), and HbA1c 68 (16) mmol/mol (8.4 (1.5) %) participated. A total of 182 and 150 meals, in week 1 and week 6, respectively, were included in the analysis of postprandial outcomes. The median (interquartile range) number of postprandial hypoglycemia episodes within 6-h after the meal was 4.5 (2.0–8.2) in week 1 versus 2.0 (0.5–6.5) in week 6 (P = 0.1). No episodes of severe hypoglycemia occurred during the study. Conclusion: The ABC4D is safe for use as a decision support tool for insulin bolus dosing in self-management of type 1 diabetes. A trend suggesting a reduction in postprandial hypoglycemia was observed in the final week compared with week 1. |
Issue Date: | 19-May-2016 |
Date of Acceptance: | 1-May-2016 |
URI: | http://hdl.handle.net/10044/1/39151 |
DOI: | http://dx.doi.org/10.1089/dia.2015.0413 |
ISSN: | 1557-8593 |
Publisher: | Mary Ann Liebert |
Start Page: | 487 |
End Page: | 493 |
Journal / Book Title: | Diabetes Technology & Therapeutics |
Volume: | 18 |
Issue: | 8 |
Copyright Statement: | © 2016 Mary Ann Liebert, Inc. The final publication is available from Mary Ann Liebert, Inc., publishers http://dx.doi.org/10.1089/dia.2015.0413. |
Sponsor/Funder: | Imperial College Healthcare NHS Trust- BRC Funding |
Funder's Grant Number: | N/A |
Keywords: | Science & Technology Life Sciences & Biomedicine Endocrinology & Metabolism |
Publication Status: | Published |
Appears in Collections: | Electrical and Electronic Engineering Faculty of Engineering |